Seer Proteograph Provides Differentiated Insights Into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery
Seer Proteograph Provides Differentiated Insights Into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery
Secretome profiles from SpaceX Inspiration4 mission show alterations in oxidative stress, brain homeostasis, and coagulation
太空探索Inspiration4任务的蛋白质组分泌谱显示出氧化应激、脑内平衡和凝血等方面的变化。
Creation of first-of-its-kind comprehensive atlas of molecular and physiological multiomic profiles available from multiple spaceflight missions
第一份全面的分子和生理多组数据图集的创建，可从多次太空飞行任务中获取。
REDWOOD CITY, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced three publications highlighting studies led by Christopher Mason, Ph.D. that show how Seer's Proteograph Product Suite can uncover novel insights into plasma proteomic changes that occur during spaceflight. The studies further demonstrate the power of the Proteograph workflow to offer scientists a deeper understanding of physiological responses and biology that can advance the development of novel biomarkers and precision medicines across a wide range of research sectors.
加利福尼亚州雷德伍德市，2024年6月11日（环球经贸新闻）-- Seer公司 (纳斯达克: SEER) 作为一家领先的生命科学公司，推出一款激进的新蛋白质组学平台，并宣布由Christopher Mason博士领导的三项研究成果。这些研究表明，Seer的Proteograph系列产品可以发现太空飞行期间发生的血浆蛋白质变化带来的新见解。而且，这些研究进一步展示了Proteograph工作流程的强大功能，为科学家提供了更深入地研究生理响应和生物学的能力，从而推进在各个研究领域开发新的生物标志物和精准医学治疗方法。Seer公司（纳斯达克：SEER）是一家领先的生命科学公司，商业化运用一种颠覆性的全新蛋白质组学平台。今天，该公司宣布发表了由Christopher Mason 博士领导的三篇研究，并在其研究成果中阐明了Seer Proteograph产品系列的功能，表明其如何揭示出太空飞行期间的血浆蛋白质变化，为科学家提供了研究生理响应和生物学的更深入的能力。这些成果展示了Proteograph工作流程的强大功能，旨在推进生物标志物和精准医学等研究领域的发展。
Omid Farokhzad, M.D., Chair & Chief Executive Officer of Seer said, "Exploring the effects of space flight on the human body presents an intriguing frontier for proteomic research. These papers highlight Seer's technology to provide unbiased insights into the proteome and shed light on dysfunctional biological alterations. At Seer, we empower researchers in detecting proteins and peptides quickly and easily, pushing the boundaries of proteomics and genomics research."
Seer的董事长及首席执行官Omid Farokhzad 博士表示，"探索太空飞行对人体的影响为蛋白质组学研究打开了一个迷人的新世界。这几篇论文强调Seer的技术可以提供无偏见的蛋白质组数据，为了解生物表征方面的异动提供了更多反思的空间。作为科学家的一种工具，Seer的 Proteograph 处理方法可以帮助科学家畅通无阻地检测蛋白质和肽段，向前推动蛋白质组学和基因组学研究的边界。"
Published in Nature, the first two manuscripts, "The Space Omics and Medical Atlas (SOMA): A comprehensive data resource and international biobank for astronauts," and "A second space age," highlight data and a sample repository for clinical, cellular, and multiomic profiles from multiple space missions, including SpaceX Inspiration4, Polaris Dawn, Axiom-2, NASA Twins Study, and JAXA Cell-Free RNA Study. The first-of-its-kind data resource, which includes plasma proteomic data generated from Seer's Proteograph workflow, offers the life sciences and aerospace communities information that could further be leveraged to study aerospace-associated physiological changes.
第一篇和第二篇手稿的题名分别为"太空组学和医学图集(SOMA)：为宇航员提供综合的数据资源和国际生物库"，以及"第二个太空时代"。这两篇手稿是发表在 ", 尤其是包括太空X Inspiration4、Polaris Dawn、Axiom-2、NASA Twins Study和JAXA细胞自由RNA Study 等多次太空任务中获取的临床、细胞和多组进化素分布的样本库数据，这是一个独一无二的数据资源，其中包括由Seer Proteograph工作流程生成的血浆蛋白质数据，为生命科学和宇航界提供了有关太空飞行期间生理变化的重要信息。Nature三篇手稿分别发表在 ",其中第一篇和第二篇手稿的题名分别为"太空组合和医学图册(SOMA)：为宇航员提供全面的数据资源和国际生物库"以及"第二个太空时代"。这两篇手稿重点介绍了从多次太空任务中获取的临床、细胞和多组进化素分布的样本库数据，包括太空X Inspiration4、Polaris Dawn、Axiom-2、NASA Twins Study和JAXA的无细胞RNA研究。第一篇手稿使得该独特的数据资源的这些点摘要可供利用。
The third manuscript, "Secretome profiling captures acute changes in oxidative stress, brain homeostasis, and coagulation following short-duration spaceflight," was published in Nature Communications, describing a study led by Dr. Mason, along with Seer scientists. In the study, the researchers profiled the secretome (plasma proteome, metabolome, and extracellular vesicles and particles) from astronauts of the first all-civilian space flight mission, the SpaceX Inspiration4, using multiple methods, including proteomic profiling from plasma using Seer's Proteograph workflow. Additionally, the scientists evaluated brain-associated changes in spaceflight mice and changes in the blood-brain barrier.
第三篇手稿的题名为"Secretome profiling captures acute changes in oxidative stress, brain homeostasis, and coagulation following short-duration spaceflight"，由Mason博士领导，并与Seer公司的科学家一起进行研究。在这项研究中，该团队使用在多种方法中提取出的astro血浆、Seer Proteograph、Western blot、周期性酶联免疫吸附实验(PELIA)、ELISA、NMR spe-labelling对小鼠进行了体外和体内的研究。此外，该研究小组对太空任务小鼠的脑相关变化以及血脑屏障变化进行了评估。no虽然作者报告称，分泌物组分的急性变化在返回地球六个月后就恢复了，但多数血浆差别丰度蛋白质的变化仍持续六个月以上，其中包括与凝血、创伤愈合、抗氧化和脑功能有关的蛋白质变化。
While the authors reported acute changes in secretome profiles that recovered six months following the return to Earth, a majority of the plasma differentially abundant proteins were still altered six months after return. More specifically, the researchers noted significant alterations in proteins involved in coagulation and wound healing, antioxidation, and brain function.
Christopher Mason博士是这些论文的第一作者，也是Seer的科学顾问委员会的成员。他说:"通过与Seer公司的合作，我们能够准确地定位出以前从未出现过的血浆蛋白质变化，涵盖了成千上万个新的蛋白质度量标准，这可以开创出新的治疗和生物标志物发现的新途径。将来，我们可以利用这些数据随着时间的推移监测身体的其他生理变化，从而创建出重点的个性化应对策略。"
Dr. Mason, lead author of the publications and member of the Seer Scientific Advisory Board, said, "Through our collaboration with Seer, we were able to pinpoint protein changes in plasma never before possible, spanning thousands of new protein metrics, which could offer new avenues of therapeutic and biomarker discovery. In the future, we can use this data to monitor additional physiological changes over time to then create focused and personalized countermeasures."
该研究（使用早期版本的Seer Proteograph技术和质谱仪）共筛选出了23,164个可与2,992个独特蛋白组相映射的肽段（蛋白和肽段FDR的截止值为1%），每个样品检测到的平均蛋白质数量为2,104个。这三张论文是44篇在各个领域中发表的太空任务论文的一部分。这些论文展示了各个任务获得的详细资料，并展示了计划在月球和火星进行的未来任务，并提供了有关获得的Proteograph数据的其他信息。
The study (which used an older version of the Seer Proteograph technology and mass spectrometer), identified a total of 23,164 peptides mapping to 2,992 unique protein groups (cutoff of 1% protein and peptide FDR), with an average of 2,104 proteins detected per sample. The three papers are part of a set of 44 space mission papers published in Nature journals today. These papers highlight the in-depth profiles from the missions, showcase the plans for upcoming missions to the moon and Mars, and provide additional information on the Proteograph data gathered.
Seer最近推出的 Proteograph XT Assay Kit 可在保持高分辨率洞察力的前提下以空前的速度、规模和深度进行无偏性的蛋白质组学研究。与下一代质谱仪一起，Proteograph XT 工作流程为科学家提供了在人类血浆研究中检测超过60,000个肽段和超过8,000个蛋白质的能力。Seer的技术为客户提供了对药物反应分析、药物新产品研发、临床研究中患者分层和精准治疗的无与伦比的见解。Nature本新闻稿包含"前瞻性声明"，根据1995年修正版"私有证券诉讼改革法"制定。此类前瞻性声明基于Seer公司的信仰和假设，以及目前可获得的信息。前瞻性声明可能涉及已知和未知的风险、不确定性和其他因素，使得Seer公司的实际结果、表现或成果与前瞻性声明所表达或暗示的结果、表现或成果实质上不同。这些声明包括但不限于以下内容：Seer的Proteograph揭示了蛋白组和蛋白质变化的新视角、深入了解了生理反应和生物学，包括了生物学的正常和异常变化、太空飞行对人体的影响、宇航员生理变化的探索、促进精准医学和生物标志物发现、具有新的蛋白质度量标准、快速轻松地检测大量的肽和蛋白质、在人类血浆研究中检测超过60,000个肽和超过8,000个蛋白质、提供对药物反应分析、药物研发、临床研究中患者分层和精准治疗的无与伦比的见解，以及推动蛋白质组学和基因组学研究速度、规模、深度和边界。
Seer's recently launched Proteograph XT Assay Kit enables unbiased proteomics research at unprecedented speed, scale, and depth while maintaining high-resolution insights. Together with next generation mass spectrometers, the Proteograph XT workflow offers scientists the capability to detect over 60,000 peptides and over 8,000 proteins in a human plasma study. Seer's technology provides customers with unparalleled insights into drug response analysis, drug discovery, patient stratifications for clinical studies, and precision medicine.
Seer的最新Proteograph XT Assay Kit可在保持高分辨率洞察力的前提下以空前的速度、规模和深度进行无偏性的蛋白质组学研究。与下一代质谱仪一起，Proteograph XT 工作流程为科学家提供了在人类血浆研究中检测超过60,000个肽段和超过8,000个蛋白质的能力。Seer的技术为客户提供了对药物反应分析、药物新产品研发、临床研究中患者分层和精准治疗的无与伦比的见解。
About Seer
关于Seer
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer's Proteograph Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer's Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Seer是一家生命科学公司，正在开发能够打开蛋白质组的新通道的创新产品。Seer Proteograph产品套件是一个综合性解决方案，包括专有的工程纳米颗粒，消耗品，自动化仪器和软件，可在几小时内在大规模进行深入、无偏的蛋白质质谱分析。Seer设计了Proteograph工作流程，使其高效易用，利用广泛采用的实验室仪器，提供分散式解决方案，可以被几乎任何实验室使用。Seer的Proteograph产品套件仅限于研究使用，不用于诊断程序。有关更多信息，请访问 www.seer.bio.
Forward-Looking Statements
前瞻性声明
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer's beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer's actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the potential of Seer's Proteograph to unveil novel unbiased insights into the proteome and proteomic changes, deeper understanding of physiological responses and biology including dysfunctional biological alterations, the effects of space flight on the human body, aerospace associated physiological changes, advance the development of therapeutic and biomarker discovery and precision medicines across a wide range of research sectors and new protein metrics, detecting proteins and peptides quickly and easily, the capability to detect large numbers of peptides and proteins, 60,000 and 8,000 respectively, in human plasma, provide unparalleled insights into drug response analysis, drug discovery, patient stratifications for clinical studies, and precision medicine, and pushing the speed, scale depth and boundaries of proteomics and genomics research. These and other risks are described more fully in Seer's filings with the Securities and Exchange Commission ("SEC") and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
本新闻稿包含"前瞻性声明"，根据1995年修正版"私有证券诉讼改革法"制定。此类前瞻性声明基于Seer公司的信仰和假设，以及目前可获得的信息。前瞻性声明可能涉及已知和未知的风险、不确定性和其他因素，使得Seer公司的实际结果、表现或成果与前瞻性声明所表达或暗示的结果、表现或成果实质上不同。这些声明包括但不限于以下内容：Seer的Proteograph揭示了蛋白组和蛋白质变化的新视角、深入了解了生理反应和生物学，包括了生物学的正常和异常变化、太空飞行对人体的影响、宇航员生理变化的探索、促进精准医学和生物标志物发现、具有新的蛋白质度量标准、快速轻松地检测大量的肽和蛋白质、在人类血浆研究中检测超过60,000个肽和超过8,000个蛋白质、提供对药物反应分析、药物新产品研发、临床研究中患者分层和精准治疗的无与伦比的见解，以及推动蛋白质组学和基因组学研究速度、规模、深度和边界。这些其他和未来的销售、运营和财务结果、回报率、收益和产出，以及其他相关的信息和事件，都可能会产生影响，而且会偏离前瞻性声明中所表述或暗示的事实、表现或结果远远超过预期。
Media Inquiries:
Patrick Schmidt
pr@seer.bio
媒体查询：
Patrick Schmidt
pr@seer.bio
Investor Inquiries:
Carrie Mendivil
investor@seer.bio
投资者咨询：
Carrie Mendivil
investor@seer.bio